生物股份(600201) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥364,004,443.89, representing a year-on-year increase of 6.54%[6] - The net profit attributable to shareholders of the listed company reached ¥106,706,586.04, marking a significant increase of 31.78% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥100,682,016.48, which is an increase of 12.21% year-on-year[6] - The basic earnings per share (EPS) for the period was ¥0.10, reflecting a 42.86% increase from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 364,004,443.89, an increase of 6.9% compared to RMB 341,659,620.42 in Q1 2022[31] - Net profit for Q1 2023 was 110,273,815.05 CNY, compared to 84,009,707.02 CNY in Q1 2022, marking an increase of about 31.2%[39] - Operating profit for Q1 2023 was 128,927,647.11 CNY, up from 106,180,710.00 CNY in Q1 2022, reflecting a growth of approximately 21.4%[39] - Basic earnings per share for Q1 2023 was 0.10 CNY, compared to 0.07 CNY in Q1 2022, indicating a rise of about 42.9%[40] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,456,276,099.18, up 1.05% from the end of the previous year[9] - The total liabilities decreased from RMB 1,039,679,567.09 at the end of 2022 to RMB 996,053,736.04 as of March 31, 2023[29] - The total equity increased from RMB 5,349,655,458.46 at the end of 2022 to RMB 5,460,222,363.14 as of March 31, 2023, indicating a growth of approximately 2.07%[29] - Cash and cash equivalents as of March 31, 2023, were RMB 1,394,807,832.70, slightly down from RMB 1,405,436,474.64 at the end of 2022[23] - The company reported a decrease in accounts payable from RMB 341,489,510.33 in Q4 2022 to RMB 354,818,061.02 in Q1 2023[31] - Accounts receivable increased to 845,801,531.54 CNY from 763,264,979.01 CNY, representing a growth of approximately 10.8%[40] - Inventory rose to 345,744,521.37 CNY from 333,456,874.44 CNY, indicating an increase of about 3.9%[40] Cash Flow - The net cash flow from operating activities was negative at -¥35,342,581.58, indicating a significant change[6] - Cash flow from operating activities in Q1 2023 was 287,890,157.06 CNY, an increase from 252,269,456.51 CNY in Q1 2022, showing a growth of approximately 14.1%[42] - The net cash flow from operating activities was -$35.34 million, compared to -$21.64 million in the previous period, indicating a decline in operational performance[44] - Total cash outflow from operating activities reached $323.23 million, up from $273.90 million year-over-year[44] - Cash inflow from investment activities was $52.48 million, down from $121.04 million in the previous period, reflecting reduced investment returns[44] - The net cash flow from investment activities was $8.44 million, a significant decrease from $76.68 million in the prior year[44] - Cash outflow from financing activities totaled $10.22 million, compared to an inflow of $9.96 million in the previous period, indicating a shift in financing strategy[44] - The ending cash and cash equivalents balance was $1.23 billion, slightly down from $1.25 billion at the end of the previous period[44] Expenses and Subsidies - The company received government subsidies amounting to ¥7,414,301.18, which are closely related to its normal business operations[9] - Total operating costs for Q1 2023 were RMB 236,832,424.14, up from RMB 227,370,832.85 in Q1 2022, reflecting a year-over-year increase of 2%[31] - Research and development expenses for Q1 2023 were RMB 25,934,361.97, slightly down from RMB 26,801,196.11 in Q1 2022[31] - The company paid $43.75 million in various taxes, an increase from $30.02 million in the prior year[44] - Cash paid for other operating activities was $79.11 million, down from $87.54 million, suggesting improved cost management[44] Other Financial Metrics - The weighted average return on equity (ROE) increased by 0.56 percentage points to 2.08%[6] - The company reported a non-recurring loss from the disposal of non-current assets amounting to -¥173,339.84[9] - The company experienced a foreign exchange impact of $137,157.59 on cash and cash equivalents[44] - The company did not adopt new accounting standards for the current reporting period[47]